Implementing Human iPSC-derived Cells in Early Safety Assessment and Disease Modeling

Presented by: Fujifilm Cellular Dynamics, Inc. and Nanion Technologies GmbH

Speakers: T.K. Feaster, PhD, Product Manager, Fujifilm Cellular Dynamics, Inc. and Sonja Stoelzle-Feix, PhD, Director, Scientific Affairs, Nanion Technologies GmbH

Part I: 12:30 – 12:45 pm
Dr. T.K. Feaster will discuss the predictive power of human iPSC-derived cells for in vitro toxicity testing. He will highlight toxicology, drug screening, and disease models. Demonstrating increased functionality and throughput valuable for identifying liabilities early in preclinical safety programs.

Part II: 12:50 – 1:20 pm
Dr. Sonja Stoelzle-Feix will discuss the effects of “CiPA drugs” on excitation-contraction coupling in iCell Cardiomyocytes2. She will describe the evaluation of the proarrhythmic potential of 23 blinded drugs on hiPSC-CMs using iCell Cardiomyocytes2 and the Nanion CardioExcyte 96 at different sites. Ion channel data and myocyte behavior will be discussed and aligned.

(Oct 2, 2018)